Marshall & Sterling Wealth Advisors Inc. Compass Therapeutics, Inc. Transaction History
Marshall & Sterling Wealth Advisors Inc.
- $148 Billion
- Q2 2025
A detailed history of Marshall & Sterling Wealth Advisors Inc. transactions in Compass Therapeutics, Inc. stock. As of the latest transaction made, Marshall & Sterling Wealth Advisors Inc. holds 200 shares of CMPX stock, worth $780. This represents 0.0% of its overall portfolio holdings.
Number of Shares
200
Previous 200
-0.0%
Holding current value
$780
Previous $380,000
36.84%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding CMPX
# of Institutions
109Shares Held
103MCall Options Held
18.2KPut Options Held
2.51M-
Orbimed Advisors LLC San Diego, CA15.2MShares$59.4 Million1.41% of portfolio
-
Tang Capital Management LLC San Diego, CA13.5MShares$52.6 Million2.1% of portfolio
-
Blackstone Inc New York, NY10MShares$39.1 Million0.12% of portfolio
-
Suvretta Capital Management, LLC New York, NY7.15MShares$27.9 Million0.64% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.06MShares$27.5 Million0.0% of portfolio
About Compass Therapeutics, Inc.
- Ticker CMPX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 101,285,000
- Market Cap $395M
- Description
- Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascula...